https://www.businesswire.com/news/home/20190412005090/en/

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2019--Life science-focused venture capital firms Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners (OUP) have partnered to create Science2Startup (S2S)™, an invitation-only symposium aimed at strengthening connections between biotech investors and therapeutics researchers at the world’s top academic research institutions. S2S will take place on April 23, 2019, in Cambridge at the Broad Institute of MIT and Harvard.

The day-long event will feature presentations of promising therapeutics in development, ones that could be part of a new generation of startups, by the participating universities’ principal investigators. There will also be a panel discussion entitled “Maintaining the Innovation Funnel – Future Trends in Funding Translatable Science," and a keynote address, “Biopharma as a Catalyst for Clinical Translation,” by Jay Bradner, President of the Novartis Institutes for BioMedical Research. Attendees at S2S will include life science-focused investors, top biotech entrepreneurs and senior individuals from the pharmaceutical industry. Evotec, Deloitte, Goodwin, JLL, and Silicon Valley Bank are the event’s sponsors.